Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 286 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

286 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

286 programs

Clinical programs

Page 6 of 6

  1. BP46037

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  2. BP46355

    Hoffmann-La Roche

    Stable Coronary Artery Disease (CAD)

    phase 1 other active

    1 trial

  3. BP46585

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  4. CO42800

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  5. CO43805

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  6. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  7. GA43191

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  8. GA46438

    Hoffmann-La Roche

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial

  9. Ipatasertib

    Hoffmann-La Roche

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  10. Midazolam

    Hoffmann-La Roche

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  11. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  12. PEG-IFN alfa-2a BA-free formulation (Test)

    Hoffmann-La Roche

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. Placebo - MAD

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  14. RO5323441

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  15. RO5503781

    Hoffmann-La Roche

    Neoplasms

    phase 1 small molecule completed

    1 trial

  16. RO5503781 MBP

    Hoffmann-La Roche

    Myelogenous Leukemia, Acute

    phase 1 small molecule completed

    1 trial

  17. RO7119929

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  18. RO7507062

    Hoffmann-La Roche

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

  19. Rugonersen

    Hoffmann-La Roche

    Angelman Syndrome (AS)

    phase 1 small molecule active

    1 trial

  20. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial

  21. WA45032

    Hoffmann-La Roche

    Hepatic Impairment

    phase 1 other active

    1 trial

  22. WN45319

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  23. WO39613

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  24. WO42758

    Hoffmann-La Roche

    Metastatic Colorectal Cancer

    phase 1 other active

    1 trial

  25. WP43295

    Hoffmann-La Roche

    BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases

    phase 1 other active

    1 trial

  26. XO45189

    Hoffmann-La Roche

    HER2-positive advanced solid tumours

    phase 1 other active

    1 trial

  27. YO45758

    Hoffmann-La Roche

    Advanced Solid Tumors Harboring RAS Mutation(S)

    phase 1 other active

    1 trial

  28. atorvastatin

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  29. balapiravir [RO4588161]

    Hoffmann-La Roche

    Dengue

    phase 1 small molecule completed

    1 trial

  30. danoprevir

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  31. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  32. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    approved small molecule completed

    1 trial

  33. BN44620

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  34. BN44621

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  35. Ganciclovir

    Hoffmann-La Roche

    Cytomegalovirus Infections

    approved small molecule completed

    1 trial

  36. Hemlibra 150 mg/mL solution for injection

    Hoffmann-La Roche

    Severe or Moderate Hemophilia A

    approved small molecule active

    1 trial

  37. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]

    approved small molecule active

    1 trial

  38. PEG-IFN alfa-2a

    Hoffmann-La Roche

    Hepatitis C, Chronic

    approved small molecule completed

    1 trial

  39. Satralizumab 120 mg

    Hoffmann-La Roche

    Neuromyelitis Optica Spectrum Disorder

    approved small molecule terminated

    1 trial

  40. Vabysmo 120 mg/mL solution for injection

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration

    approved small molecule active

    1 trial

  41. Vemurafenib

    Hoffmann-La Roche

    Neoplasms

    approved small molecule completed

    1 trial

  42. docetaxel

    Hoffmann-La Roche

    Breast Cancer

    approved small molecule completed

    2 trials

  43. epoetin beta [NeoRecormon]

    Hoffmann-La Roche

    Anemia

    approved small molecule terminated

    1 trial

  44. ibandronate [Bonviva/Boniva]

    Hoffmann-La Roche

    Post Menopausal Osteoporosis

    approved small molecule completed

    1 trial

  45. methoxy polyethylene glycol-epoetin beta [Mircera]

    Hoffmann-La Roche

    Anemia

    approved small molecule terminated

    2 trials

  46. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Gastric Cancer

    approved small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.